Article: Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature

Tenofovir disoproxil fumarate (TDF) is a potent nucleotide analogue with high barrier to resistance, which is recommended for multi-drug resistant hepatitis B virus (HBV) infection. However, nephrotoxicity has been reported during TDF treatment, and tenofovir alafenamide (TAF), which has comparable efficacy to TDF and improves bone and renal safety, can be used as a replacement strategy. Herein, we describe a clinical case concerning a 60-year-old individual suffering liver cirrhosis and renal dysfunction, and being infected with multidrug-resistant HBV. When failing treatment with TDF, he received TAF as a rescue therapy. TAF effectively inhibited HBV replication without worsening renal function or serum phosphorus abnormality. Furthermore, hepatocellular carcinoma (HCC) occurred during TAF treatment despite controlling the viral load. The risk of HCC could not be eliminated and should be monitored during TAF treatment.

Citing Articles

High Frequency of Antiviral Resistance Mutations in HBV Genotypes A2 and H: Multidrug Resistance Strains in Mexico.

Jose-Abrego A, Roman S, Pinho J, Gomes-Gouvea M, Panduro A J Clin Transl Hepatol. 2023; 11(5):1023-1034.

PMID: 37577226 PMC: 10412697. DOI: 10.14218/JCTH.2022.00135S.

Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms.

Mokaya J, McNaughton A, Bester P, Goedhals D, Barnes E, Marsden B Wellcome Open Res. 2021; 5:151.

PMID: 33869791 PMC: 8033640. DOI: 10.12688/wellcomeopenres.15992.1.

Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.

Li J, Qin X, Wu R, Wan L, Zhang L, Liu R J Cell Mol Med. 2020; 24(9):5152-5161.

PMID: 32222024 PMC: 7205830. DOI: 10.1111/jcmm.15162.

References

1.

Wong G, Seto W, Wong V, Yuen M, Chan H . Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018; 47(6):730-737. DOI: 10.1111/apt.14497. View

2.

Zoulim F, Locarnini S . Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137(5):1593-608.e1-2. DOI: 10.1053/j.gastro.2009.08.063. View

3.

Lim Y, Yoo B, Byun K, Kwon S, Kim Y, An J . Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2015; 65(6):1042-51. DOI: 10.1136/gutjnl-2014-308435. View

4.

Zoulim F, Bialkowska-Warzecha J, Diculescu M, Goldis A, Heyne R, Mach T . Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatol Int. 2016; 10(5):779-88. DOI: 10.1007/s12072-016-9737-2. View

5.

Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E . Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol. 2017; . DOI: 10.1016/j.jhep.2017.08.020. View

6.

Buti M, Riveiro-Barciela M, Esteban R . Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. J Infect Dis. 2017; 216(suppl_8):S792-S796. DOI: 10.1093/infdis/jix135. View

7.

Zhang H, Liu L, Ye C, Chen C, Hang S, Zhu Z . Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016). Virus Genes. 2017; 54(1):41-47. DOI: 10.1007/s11262-017-1518-z. View

8.

Marcellin P, Zoulim F, Hezode C, Causse X, Roche B, Truchi R . Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Dig Dis Sci. 2016; 61(10):3072-3083. PMC: 5020114. DOI: 10.1007/s10620-015-4027-8. View

9.

Vigano M, Brocchieri A, Spinetti A, Zaltron S, Mangia G, Facchetti F . Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. J Clin Virol. 2014; 61(4):600-3. DOI: 10.1016/j.jcv.2014.09.016. View

10.

Buti M, Gane E, Seto W, Chan H, Chuang W, Stepanova T . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2017; 1(3):196-206. DOI: 10.1016/S2468-1253(16)30107-8. View

Incident Hepatocellular Carcinoma Developing During Tenofovir Alafenamide Treatment As a Rescue Therapy for Multi-drug Resistant Hepatitis B Virus Infection: A Case Report and Review of the Literature